CN104661649A - A solid oral pharmaceutical formulation containing ticagrelor - Google Patents

A solid oral pharmaceutical formulation containing ticagrelor Download PDF

Info

Publication number
CN104661649A
CN104661649A CN201380050404.5A CN201380050404A CN104661649A CN 104661649 A CN104661649 A CN 104661649A CN 201380050404 A CN201380050404 A CN 201380050404A CN 104661649 A CN104661649 A CN 104661649A
Authority
CN
China
Prior art keywords
preparation according
hygroscopic
preparation
cellulose
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380050404.5A
Other languages
Chinese (zh)
Inventor
格雷戈尔·塞德马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of CN104661649A publication Critical patent/CN104661649A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present solution provides a solid oral pharmaceutical formulation containing ticagrelor, in the chemical name (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]- 5-(propylthio)-3H-1,2,3-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)-1,2- cyclopentanediol, comprising at least one non-hygroscopic filler and/or at least one non- hygroscopic binder, wherein neither the filler, nor the binder have any disintegration effect. Preparation of the formulation is possible by wet granulation or dry granulation or direct.

Description

Comprise the solid oral pharmaceutical preparation of ticagrelor
Technical field
The present invention relates to the preparation method comprising solid oral pharmaceutical preparation that ticagrelor (ticagrelor) forms as active medicaments and said preparation.
Background technology
What represented by formula (I) has chemical name (1S, 2S, 3R, 5S)-3-[7-[[(1R, 2S)-2-(3,4-difluorophenyl) cyclopropyl] is amino]-5-(rosickyite base)-3H-1,2,3-triazol [4,5-d] pyrimidin-3-yl] the compound ticagrelor of-5-(2-hydroxyl-oxethyl)-1,2-ring pentanediol
In WO 1999/005143, there is description general and mention particularly in EP 1 135 391.This document also illustrates its preparation method, and the purposes of ticagrelor in treatment or prevention myocardial infarction, apoplexy, peripheral vascular disease etc.
WO 2001/092262 describes 4 kinds of polymorph and a kind of amorphous form of ticagrelor.WO 2011/067571 describes the eutectic with multiple coforming thing (coformer) (such as glycolic, salicylic acid, succinic acid, malonic acid and 4-hydroxy 3-methoxybenzene carboxylic acid).
Described by pharmaceutical preparation has in 2 sections of application WO 2008/024044 and WO 2008/024045 of company Astra Zeneca.WO 2008/024044 describes a kind of solid formulation, and it comprises one or more filleies, one or more binding agents, preferably one or more disintegrating agents and preferably one or more lubricants.According to the embodiment 1 of WO 2008/024044, by Sodium carboxymethyl starch with 3 % by weight amount be used as disintegrating agent.Any embodiment not using disintegrating agent do not mentioned by document.WO2008/024045 describes a kind of extremely similar solid formulation, and it comprises one or more filleies, one or more binding agents, preferably one or more disintegrating agents and preferably one or more lubricants.This document points out that the use of disintegrating agent is required.The specific embodiment mentioned in the document comprises the disintegrating agent of 2-6 % by weight, and this disintegrating agent is Sodium carboxymethyl starch.
WO 2011/076749 relates to the granularity of ticagrelor used in the formulation, because knowing ticagrelor is a kind of insoluble chemical compound.In the embodiment quoted from this application, disintegrating agent uses with the amount in 4-6 % by weight scope.
Ticagrelor sells with trade name Brilique with the form prevention antithrombus formation event in coated tablet.Commercial preparation also comprises the Sodium carboxymethyl starch as disintegrating agent.
Summary of the invention
The present invention relates to a kind of solid oral pharmaceutical preparation, it comprises and has chemical name (1S, 2S, 3R, 5S)-3-[7-[[(1R, 2S)-2-(3,4-difluorophenyl) cyclopropyl] amino]-5-(rosickyite base)-3H-1,2,3-triazol [4,5-d] pyrimidin-3-yl] ticagrelor of-5-(2-hydroxyl-oxethyl)-1,2-ring pentanediol, comprise again at least one non-hygroscopic bulking agent and/or at least one non-hygroscopic binding agent without disintegrate effect.
Detailed description of the invention
Non-hygroscopic bulking agent means water-soluble filler, general preferred sugar alcohol, such as glucose, fructose, sucrose, lactose monohydrate, Lactis Anhydrous, Raffinose, dextrinose, trehalose, dextrates (dextrates), mannitol, erythritol, Sorbitol, maltose alcohol, xylitol, lactose, sompressible sugar.Such as, hydroxypropyl cellulose or maltose can be used as non-hygroscopic binding agent.0.5-30 % by weight binding agent is preferably comprised, preferably 1-7 % by weight binding agent and most preferably 2-4 % by weight binding agent according to compositions of the present invention.
Term non-hygroscopic as used in the present invention refers to a kind of material with low reception and fixing moisture content ability.Or express in a better way, term non-hygroscopic refers to a kind of material of equilibrium moisture content had lower than 6 % by weight.This value be by dynamic vapor sorption (DVS) 60% relative humidity and temperature 25 DEG C at determine.Equilibrium moisture content be based on utilize DVS method 60% relative humidity and temperature 25 DEG C at measure adsorption isothermal curve determine.
Those skilled in the art understand disintegrating agent use in the formulation does not need the bioavailability on increasing active substance to have impact.This character affects by the sufficient humidifying of the active substance existed in preparation more.Do not using general's rapidly-soluble compositions fully under disintegrating agent if can obtain, then disintegrating agent self can become a kind of unnecessary composition without any actual effect.
Disintegrating agent representative is regarded as a class excipient of special excipient usually.The price of the cost ratio usual excipients (such as filler) of special excipient (such as disintegrating agent) exceeds a lot.The price of disintegrating agent (such as Sodium carboxymethyl starch or cross-linking sodium carboxymethyl cellulose salt) is generally several times of the price of common filler (such as mannitol or calcium hydrogen phosphate).
The model of action of disintegrating agent so far and unclear.The mechanism thought in the past comprises, and such as, water-soaked, expansion, shape memory, to heat during the repellency of other component, humidifying.It is most important for effective disintegrate that disintegrating agent makes water enter the ability of tablet perforated web.This explanation is by pharmaceutical technology encyclopedia (Encyclopaedia of Pharmaceutical Technology), the third phase, InformaHealthcare USA, Inc., and 2007 provide.As the natural result making water enter the ability of tablet, disintegrating agent is generally hygroscopicity or strong hygroscopic matter.According to pharmaceutic adjuvant handbook (Handbook ofPharmaceutical Excipients), 6th phase, Pharmaceutical Press (Pharmaceutical Press), 2009, cross-linking sodium carboxymethyl cellulose salt and Sodium carboxymethyl starch show same characteristic features.
Due to the hygroscopic nature of excipient, it is required for being encapsulated in by ticagrelor preparation in PVC/PVDC bubble-cap.The use of non-hygroscopic blister package makes expensive PVS/PVDC be substituted by more economical PVC bubble-cap becomes possibility.About excipient and the lower packing cost of more low cost, the preparation comprising the non-hygroscopic excipient without any disintegrate effect need be obtained.
WO2008/024045 describe comprise one or more filleies, one or more binding agents, preferably one or more disintegrating agents and preferably the use of the compositions of one or more lubricants be suitable for discharging at least 90% ticagrelor fully.Be different from the discovery of prior art, we have found to comprise does not have the ticagrelor compositions with the ticagrelor of any form known (crystal, amorphous or co-crystal forms) of at least one non-hygroscopic bulking agent of disintegrate effect characteristic and/or at least one non-hygroscopic binding agent to reach effective release of at least 90% ticagrelor.
As used herein, term " disintegrating agent " abutment water expands or any material of soaking.Term disintegrating agent including (for example) lower group of compound, such as polyvidone, crospovidone, starch, pregelatinized starch, sanlose, hydroxypropyl starch, microcrystalline Cellulose, carboxymethylcellulose calcium salt, cross-linked carboxymethyl cellulose sodium salt, polacrilin potassium salt, low-substituted hydroxypropyl cellulose, sodium alginate, calcium alginate, docusate sodium, methylcellulose, agar, guar gum, chitosan and alginic acid.Ticagrelor compositions should not comprise or comprise and is less than 2% disintegrating agent.
In the most preferred embodiment, the medical composition of ticagrelor does not comprise disintegrating agent substantially.
Ticagrelor compositions comprises non-hygroscopic bulking agent.In general, preferred water soluble filler.Suitable fillers is (such as) monosaccharide, oligosaccharide and sugar alcohol, such as glucose, fructose, sucrose, lactose monohydrate, Lactis Anhydrous, Raffinose, dextrinose, trehalose, dextrates, mannitol, erythritol, Sorbitol, maltose alcohol, xylitol and lactose, sompressible sugar, dicalcium phosphate dihydrate and their mixture.Preferred lactose, mannitol and xylitol.
Ticagrelor compositions comprises non-hygroscopic binding agent.Suitable binders is (such as) polyvidone, copolyvidone, the crystal of powdered or microcrystalline Cellulose, silicified microcrystalline cellulose, cellulose derivative, such as hydroxy methocel, hydroxyethyl-cellulose and hydroxypropyl emthylcellulose, starch, pregelatinized starch, polymethacrylates and their mixture.In a preferred compositions, the preparation of ticagrelor comprises 0.5 to 30 % by weight binding agent, and preferably 1 to 7%, optimally 2 to 4 % by weight binding agents.
Ticagrelor compositions generally comprises at least one surfactant.Suitable surfactant is (such as) anionic surfactant, cationic surface active agent, amphoteric surfactant and/or nonionic surfactant, such as lauryl sulfate sodium salt, cetab (cetrimide), N-dodecyl-N, N-dimethyl betaine, polysorbate are (such as ), poloxamer and their mixture.Lauryl sulfate sodium salt is preferred compound.The use amount of surfactant in ticagrelor preparation is 0.1 to 4.0 % by weight, most preferably 0.5 to 2.0%.
Ticagrelor compositions generally comprises at least one lubricant and/or stick resistant compound, and it selects in (such as) magnesium stearate, stearic acid, hydrogenated vegetable oil, castor oil hydrogenated, Talcum, sodium stearyl fumarate, colloidal silica, magnesium trisilicate and their mixture.Particularly preferably stearic acid, magnesium stearate, sodium stearyl fumarate and colloidal silica.
Ticagrelor tablet should by any suitable coatings.The Suitable coatings agent of ticagrelor tablet is selected from (such as) methylcellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, acrylic acid polymer, ethyl cellulose, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl alcohol, sanlose, cellulose acetate, gelatin, the copolymer of methacrylic acid, Polyethylene Glycol, Lac, sucrose, titanium dioxide and Brazil wax.Preferred Polyethylene Glycol, hydroxypropyl emthylcellulose and polyvinyl alcohol.
Embodiment
Embodiment 1
Wet granulation
The aqueous solution of hydroxypropyl cellulose or maltose is utilized to make ticagrelor and lactose monohydrate or xylitol or mannitol or maltose alcohol granulate (granulated by kneading or utilize the common pellet fabrication device with fluid bed to granulate) in a wetted condition.Preferably, sodium lauryl sulfate is added in granulation solution.Make gained particle drying and by 1mm sieved through sieve.Then, sieved granule and lactose monohydrate or xylitol or mannitol or dextrinose or maltose are mixed 20 minutes in suitable mixing arrangement.After this premixing, magnesium stearate to be added in mixture and to make this mixture stir 3 minutes again, thus the press sheet mixture that is suitable for can be obtained.Then, in the preforming device rotated, this mixture is compressed into tablet.
Embodiment 2
Dry granulation
In the rotary compressor with variable gap size, in dry conditions, make ticagrelor and mannitol or lactose monohydrate or xylitol and preferably granulate with sodium lauryl sulfate.Make gained granule by 1mm sieved through sieve.Sieved granule and lactose monohydrate or xylitol or mannitol or dextrinose or maltose or lactose are mixed 20 minutes in suitable mixing arrangement.After premixing, magnesium stearate to be added in mixture and to make this mixture stir 3 minutes again, thus can obtain can the mixture of tabletting.Then, in the preforming device rotated, this mixture is compressed into tablet.
Embodiment 3
Direct compression
3A 3B 3C 3D 3E 3F
Ticagrelor Active substance 90.0 90.0 90.0 90.0 90.0 90.0
Lactose monohydrate Filler 204.0
Xylitol Filler 204.0
Mannitol Filler 204.0
Dextrinose Filler 204.0
Maltose Filler 204.0
Lactose Filler 204.0
Magnesium stearate Lubricant 6.0 6.0 6.0 6.0 6.0 6.0
Altogether (mg) 300.0 300.0 300.0 300.0 300.0 300.0
Ticagrelor and lactose monohydrate or xylitol or mannitol or dextrinose or maltose or lactose is made to mix 20 minutes in suitable mixing arrangement.After premixing, magnesium stearate to be added in mixture and to make this mixture stir 3 minutes again, thus can obtain in the preforming device rotated can the mixture of tabletting.
Embodiment 4
Tablet is coated
The coated tablet obtained according to embodiment 1 to 3 of common coating material should be utilized.
4A 4B 4C
Hydroxypropyl emthylcellulose 7.0
Polyvinyl alcohol 7.0
Hydroxypropyl cellulose 7.0
Polyethylene Glycol 1.5 1.5 1.5
Talcum 0.5 0.5 0.5
Titanium dioxide 0.5 0.5 0.5
Yellow ferric oxide 0.5 0.5 0.5
Altogether (mg) 10.0 10.0 10.0
By the components dissolved of coating blend or be suspended in enough water to provide Coating Solution.Then, in suitable device, utilize this solution coated tablets and finally make them dry.

Claims (13)

1. a solid pharmaceutical composition, it comprises and has chemical name (1S, 2S, 3R, 5S)-3-[7-[[(1R, 2S)-2-(3,4-difluorophenyl) cyclopropyl] amino]-5-(rosickyite base)-3H-1,2,3-triazol [4,5-d] pyrimidin-3-yl] ticagrelor of-5-(2-hydroxyl-oxethyl)-1,2-ring pentanediol, it is characterized in that this solid pharmaceutical composition comprises at least one non-hygroscopic bulking agent and/or at least one non-hygroscopic binding agent.
2. preparation according to claim 1, is characterized in that described non-hygroscopic bulking agent and non-hygroscopic binding agent do not have any disintegrate effect.
3. preparation according to claim 2, is characterized in that described non-hygroscopic bulking agent is selected from the group be made up of sugar alcohol such as glucose, fructose, sucrose, lactose monohydrate, Lactis Anhydrous, Raffinose, dextrinose, trehalose, dextrates, mannitol, erythritol, Sorbitol, maltose alcohol, xylitol, lactose and sompressible sugar.
4. preparation according to claim 2, is characterized in that described non-hygroscopic binding agent is selected from hydroxypropyl cellulose and maltose.
5. the preparation according to claim 1-4, is characterized in that described compositions also comprises at least one lubricant, optional at least one surfactant and the preferred amount at least one disintegrating agent in 0 to 2 % by weight scope.
6. preparation according to claim 5, it is characterized in that another kind of binding agent is selected from and comprise polyvidone, copolyvidone, the crystal of powdered or microcrystalline Cellulose, silicified microcrystalline cellulose, cellulose derivative, the group of such as hydroxy methocel, hydroxyethyl-cellulose and hydroxypropyl emthylcellulose, starch, pregelatinized starch, polymethacrylates and their mixture.
7. preparation according to claim 5, is characterized in that described lubricant is selected from stearic acid, magnesium stearate or sodium stearyl fumarate.
8. preparation according to claim 5, it is characterized in that described surfactant is selected from and comprise anionic surfactant, cationic surface active agent, amphoteric surfactant or nonionic surfactant such as lauryl sulfate sodium salt, cetab, N-dodecyl-N, the group of N-dimethyl betaine, polysorbate, poloxamer and their mixture.
9. preparation according to claim 5, is characterized in that another kind of disintegrating agent is selected from the group comprising polyvidone, crospovidone, starch, pregelatinized starch, sanlose, hydroxypropyl starch, microcrystalline Cellulose, carboxymethylcellulose calcium salt, cross-linking sodium carboxymethyl cellulose salt and low-substituted hydroxypropyl cellulose.
10. the preparation according to claim 1-9, is characterized in that described compositions provides coating.
11. 1 kinds of methods being prepared in the preparation defined in claim 1-10, is characterized in that it is prepared by wet granulation.
12. 1 kinds of methods being prepared in the preparation defined in claim 1-10, is characterized in that it is prepared by dry granulation.
13. 1 kinds of methods being prepared in the preparation defined in claim 1-10, is characterized in that it is by directly compressing preparation.
CN201380050404.5A 2012-10-16 2013-10-15 A solid oral pharmaceutical formulation containing ticagrelor Pending CN104661649A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZPV2012-705 2012-10-16
CZ2012-705A CZ2012705A3 (en) 2012-10-16 2012-10-16 Solid oral pharmaceutical formulation containing ticagrelor
PCT/CZ2013/000130 WO2014059955A1 (en) 2012-10-16 2013-10-15 A solid oral pharmaceutical formulation containing ticagrelor

Publications (1)

Publication Number Publication Date
CN104661649A true CN104661649A (en) 2015-05-27

Family

ID=49619770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380050404.5A Pending CN104661649A (en) 2012-10-16 2013-10-15 A solid oral pharmaceutical formulation containing ticagrelor

Country Status (13)

Country Link
EP (1) EP2908802A1 (en)
JP (1) JP6301934B2 (en)
KR (1) KR20150067153A (en)
CN (1) CN104661649A (en)
BR (1) BR112015008076A2 (en)
CZ (1) CZ2012705A3 (en)
EA (1) EA201590745A1 (en)
HK (1) HK1205456A1 (en)
IL (1) IL238036B (en)
MX (1) MX2015003866A (en)
UA (1) UA116784C2 (en)
WO (1) WO2014059955A1 (en)
ZA (1) ZA201501954B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105193759A (en) * 2015-09-18 2015-12-30 乐普药业股份有限公司 Ticagrelor tablet and preparing method thereof
CN106667926A (en) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 Favipiravir tablets and preparation method thereof
CN107530288A (en) * 2016-04-21 2018-01-02 阿斯利康(瑞典)有限公司 Oral disnitegration tablet

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160012706A (en) * 2014-07-25 2016-02-03 동아에스티 주식회사 Sustained release formulations
CN111588702B (en) * 2015-04-29 2023-01-20 江苏恒瑞医药股份有限公司 Ticagrelor preparation of pharmaceutically acceptable salt thereof
TR201601835A2 (en) * 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi PRODUCTION METHOD FOR FORMULATIONS CONTAINING TIKAGRELOR
TR201617983A2 (en) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF TICAGRELOR
KR102610876B1 (en) * 2018-03-05 2023-12-06 주식회사 파마코스텍 Crystal form I of Ticagrelor Fumarateand its preparing method
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
EP3829547A1 (en) 2018-07-27 2021-06-09 KRKA, d.d., Novo mesto Pharmaceutical composition of ticagrelor
CN111450067A (en) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 Ticagrelor dispersible tablet and preparation method thereof
CN116370423A (en) * 2023-02-28 2023-07-04 天津力生制药股份有限公司 Ticagrelor orally disintegrating tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1432018A (en) * 2000-06-02 2003-07-23 阿斯特拉曾尼卡有限公司 Crystalline and amorphous form of triazolo (4,5-d) pyrimidine compound
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
CN101505754A (en) * 2006-08-21 2009-08-12 阿斯利康(瑞典)有限公司 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530058B (en) 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
JPH11199517A (en) * 1997-10-31 1999-07-27 Meiji Seika Kaisha Ltd Intraoral fast disintegrable tablet
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
WO2007018057A1 (en) * 2005-08-05 2007-02-15 Freund Corporation Tablet rapidly disintegrating in the oral cavity and method of producing the same
RU2012126029A (en) 2009-12-03 2014-01-10 Астразенека Аб CO-CRYSTALS OF TRIAZOLO [4,5 D] PYRIMIDINE INHIBITOR OF THROMBOCYTES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1432018A (en) * 2000-06-02 2003-07-23 阿斯特拉曾尼卡有限公司 Crystalline and amorphous form of triazolo (4,5-d) pyrimidine compound
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
CN101505754A (en) * 2006-08-21 2009-08-12 阿斯利康(瑞典)有限公司 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2011076749A3 (en) * 2009-12-23 2011-08-18 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105193759A (en) * 2015-09-18 2015-12-30 乐普药业股份有限公司 Ticagrelor tablet and preparing method thereof
CN105193759B (en) * 2015-09-18 2018-07-03 乐普药业股份有限公司 A kind of ticagrelor piece and preparation method thereof
CN106667926A (en) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 Favipiravir tablets and preparation method thereof
CN106667926B (en) * 2015-11-09 2020-01-17 石药集团中奇制药技术（石家庄）有限公司 Favipiravir tablet and preparation method thereof
CN107530288A (en) * 2016-04-21 2018-01-02 阿斯利康(瑞典)有限公司 Oral disnitegration tablet
CN107530288B (en) * 2016-04-21 2022-01-25 阿斯利康(瑞典)有限公司 Orally disintegrating tablet

Also Published As

Publication number Publication date
BR112015008076A2 (en) 2017-07-04
UA116784C2 (en) 2018-05-10
MX2015003866A (en) 2015-07-17
EP2908802A1 (en) 2015-08-26
JP6301934B2 (en) 2018-03-28
KR20150067153A (en) 2015-06-17
EA201590745A1 (en) 2015-08-31
HK1205456A1 (en) 2015-12-18
IL238036A0 (en) 2015-05-31
IL238036B (en) 2019-05-30
ZA201501954B (en) 2017-04-26
WO2014059955A1 (en) 2014-04-24
CZ2012705A3 (en) 2014-04-23
JP2015533129A (en) 2015-11-19

Similar Documents

Publication Publication Date Title
CN104661649A (en) A solid oral pharmaceutical formulation containing ticagrelor
JP6399115B2 (en) Solid pharmaceutical composition containing a compound having angiotensin II antagonistic activity
CN101312714A (en) Medicament composition of telmisartan
KR20120046766A (en) Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles
EP3384901B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
EP3003277B1 (en) Process for the preparation of a pharmaceutical composition comprising rivaroxaban
JP7336388B2 (en) Tablet and its manufacturing method
JP7094944B2 (en) Pharmaceutical composition containing rosuvastatin and ezetimibe and method for preparing the same
WO2020070147A1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2012136839A1 (en) Dry formulation and pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2012100948A1 (en) Pharmaceutical compositions comprising tasocitinib
WO2011080706A1 (en) Enhanced solubility of ziprasidone
CN102846573B (en) Silibinin double-layer slow-release tablets and preparation method thereof
KR20110085307A (en) Oral solid dosage form comprising poorly soluble drugs
JP2014037356A (en) Candesartan cilexetil oral formulation
EP3829547A1 (en) Pharmaceutical composition of ticagrelor
JP2013203690A (en) Intraorally disintegrating tablet and method for producing the same
CN102247367A (en) Pharmaceutical composition containing telmisartan and amlodipine and preparation method thereof
WO2014091263A1 (en) Telmisartan containing pharmaceutical composition
US10010529B2 (en) Extended release pharmaceutical formulations with controlled impurity levels
WO2014122671A2 (en) Solid oral compositions of saxagliptin
WO2008145361A1 (en) Mineral-fiber solid dispersion, method for preparing the same, and use thereof as pharmaceutical tableting aid
CZ30477U1 (en) A solid oral pharmaceutical formulation comprising ticagrelor
JP2014040379A (en) Production method of tablet containing hydrophobic drug

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205456

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150527

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1205456

Country of ref document: HK